Molecular Imaging最新文献_第3页

A Decade's Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor. 以生长激素促分泌素受体为靶点的分子显像剂的研究进展

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120952623

Marina D Childs, Leonard G Luyt

{"title":"A Decade's Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor.","authors":"Marina D Childs, Leonard G Luyt","doi":"10.1177/1536012120952623","DOIUrl":"https://doi.org/10.1177/1536012120952623","url":null,"abstract":"The growth hormone secretagogue receptor 1a (GHSR), also called the ghrelin receptor, is a G protein-coupled receptor known to play an important metabolic role in the regulation of various physiological processes, including energy expenditure, growth hormone secretion, and cell proliferation. This receptor has been implicated in numerous health issues including obesity, gastrointestinal disorders, type II diabetes, and regulation of body weight in patients with Prader-Willi syndrome, and there has been growing interest in studying its mechanism of behavior to unlock further applications of GHSR-targeted therapeutics. In addition, the GHSR is expressed in various types of cancer including prostate, breast, and testicular cancers, while aberrant expression has been reported in cardiac disease. Targeted molecular imaging of the GHSR could provide insights into its role in biological processes related to these disease states. Over the past decade, imaging probes targeting this receptor have been discovered for the imaging modalities PET, SPECT, and optical imaging. High-affinity analogues of ghrelin, the endogenous ligand for the GHSR, as well as small molecule inhibitors have been developed and evaluated both in vitro and in pre-clinical models. This review provides a comprehensive overview of the molecular imaging agents targeting the GHSR reported to the end of 2019.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120952623"},"PeriodicalIF":2.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120952623","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38528878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

From the Outside in: An Overview of Positron Imaging of Plant and Soil Processes. 从外到内:植物和土壤过程的正电子成像综述。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120966405

Michael P Schmidt, Steven D Mamet, Richard A Ferrieri, Derek Peak, Steven D Siciliano

{"title":"From the Outside in: An Overview of Positron Imaging of Plant and Soil Processes.","authors":"Michael P Schmidt, Steven D Mamet, Richard A Ferrieri, Derek Peak, Steven D Siciliano","doi":"10.1177/1536012120966405","DOIUrl":"https://doi.org/10.1177/1536012120966405","url":null,"abstract":"Positron-emitting nuclides have long been used as imaging agents in medical science to spatially trace processes non-invasively, allowing for real-time molecular imaging using low tracer concentrations. This ability to non-destructively visualize processes in real time also makes positron imaging uniquely suitable for probing various processes in plants and porous environmental media, such as soils and sediments. Here, we provide an overview of historical and current applications of positron imaging in environmental research. We highlight plant physiological research, where positron imaging has been used extensively to image dynamics of macronutrients, signalling molecules, trace elements, and contaminant metals under various conditions and perturbations. We describe how positron imaging is used in porous soils and sediments to visualize transport, flow, and microbial metabolic processes. We also address the interface between positron imaging and other imaging approaches, and present accompanying chemical analysis of labelled compounds for reviewed topics, highlighting the bridge between positron imaging and complementary techniques across scales. Finally, we discuss possible future applications of positron imaging and its potential as a nexus of interdisciplinary biogeochemical research.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120966405"},"PeriodicalIF":2.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120966405","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38548086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Evaluation of Imaging Windows for Tau PET Imaging Using ¹⁸F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients. 认知正常个体、轻度认知障碍和阿尔茨海默病患者使用18F-PI2260进行Tau PET成像的成像窗口评估。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120947582

Chanisa Chotipanich, Monchaya Nivorn, Anchisa Kunawudhi, Chetsadaporn Promteangtrong, Natphimol Boonkawin, Attapon Jantarato

{"title":"Evaluation of Imaging Windows for Tau PET Imaging Using 18F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients.","authors":"Chanisa Chotipanich, Monchaya Nivorn, Anchisa Kunawudhi, Chetsadaporn Promteangtrong, Natphimol Boonkawin, Attapon Jantarato","doi":"10.1177/1536012120947582","DOIUrl":"10.1177/1536012120947582","url":null,"abstract":"Background: The study aimed to evaluate the appropriate uptake-timing in cognitively normal individuals, mild cognitive impairment (MCI), and Alzheimer's disease (AD) patients, using 18F-PI 2620 dynamic PET acquisition.Methods: Thirty-four MCI patients, 6 AD patients, and 24 cognitively normal individuals were enrolled in this study. A dynamic 18F-PI 2620 PET study was conducted at 30-75 minutes post-injection in these groups. Co-registration was applied between the dynamic acquisition PET and T1-weighted MRI to delineate various cortical regions. The standardized uptake value ratio (SUVR) was used for quantitative analysis. P-mod software with the Automated Anatomical Labeling (AAL)-merged atlas was employed to generate automatic volumes of interest for 11 brain regions.Results: The curves in most brain regions presented an average SUVR stability at 30-40 minutes post-injection in each group. The appropriate uptake-timing interval of 18F-PI 2620 was 30-75 minutes post injection for AD group and 30-40 minutes post injection for both cognitively normal individuals and MCI groups.Conclusion: Short uptake time around 30-40 minutes post-injection would be more comfortable and convenient for all patients, especially in those with dementia who were unable to stay motionless for long periods of scanning time in the scanner.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120947582"},"PeriodicalIF":2.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120947582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38325157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions. 神经科学的放射性核素成像:当前的观点和未来的方向。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120936397

Antony D Gee, Matthias M Herth, Michelle L James, Aruna Korde, Peter J H Scott, Neil Vasdev

引用次数: 3

Peptide Based Imaging Agents for HER2 Imaging in Oncology. 肿瘤HER2成像的肽基显像剂。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120960258

Maxwell Ducharme, Suzanne E Lapi

{"title":"Peptide Based Imaging Agents for HER2 Imaging in Oncology.","authors":"Maxwell Ducharme, Suzanne E Lapi","doi":"10.1177/1536012120960258","DOIUrl":"https://doi.org/10.1177/1536012120960258","url":null,"abstract":"Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has approved receptor-based therapies including trastuzumab and pertuzumab that can significantly increase the likelihood of survival. Current methods to determine HER2 status include biopsies with immunohistochemical staining and/or fluorescence in situ hybridization. However, positron emission tomography (PET) imaging techniques using 89Zr-trastuzumab or 89Zr-pertuzumab are currently in clinical trials for a non-invasive, full body diagnostic approach. Although the antibodies have strong specificity to the HER2 positive lesions, challenges involving long post-injection time for imaging due to the blood circulation of the antibodies and matching of long-live isotopes leading to increased dose to the patient leave opportunities for alternative PET imaging probes. Peptides have been shown to allow for shorter injection-to-imaging time and can be used with shorter lived isotopes. HER2 specific peptides under development will help improve the diagnosis and potentially therapy options for HER2 positive breast cancer. Peptides showing specificity for HER2 could start widespread development of molecular imaging techniques for HER2 positive cancers.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120960258"},"PeriodicalIF":2.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120960258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38403380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Targeted Imaging Agent to HSP70 Induced In Vivo. 靶向显像剂对体内诱导HSP70的影响。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120942685

Pradip Ghosh, Brian E O'Neill, King C Li

引用次数: 0

Magnetofluorescent Nanoprobe for Multimodal and Multicolor Bioimaging. 用于多模态和多色生物成像的磁荧光纳米探针。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120969477

Aditya Yadav, Chethana Rao, Navneet Chandra Verma, Pushpendra Mani Mishra, Chayan Kanti Nandi

引用次数: 1

Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy. 放射标记Asn-Gly-Arg (NGR)肽在成像和治疗中的研究进展。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120934957

Liqin Zhu, Zhikai Ding, Xingliang Li, Hongyuan Wei, Yue Chen

引用次数: 13

Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy. 两例伴随诊断免疫-正电子发射断层扫描(PET)示踪剂用于检测抗体药物偶联(ADC)治疗中癌症中人类CA6表达的患者研究。

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120939398

Arutselvan Natarajan, Shyam M Srinivas, Carmen Azevedo, Lacey Greene, Anne-Laure Bauchet, Erwan Jouannot, Anne-Sophie Lacoste-Bourgeacq, Isabelle Guizon, Patrick Cohen, Anne-Laure Naneix, Ohad Ilovich, Jordan Cisneros, Krithika Rupanarayan, Frederick T Chin, Andrei Iagaru, Frederick M Dirbas, Amer Karam, Sanjiv S Gambhir

{"title":"Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy.","authors":"Arutselvan Natarajan, Shyam M Srinivas, Carmen Azevedo, Lacey Greene, Anne-Laure Bauchet, Erwan Jouannot, Anne-Sophie Lacoste-Bourgeacq, Isabelle Guizon, Patrick Cohen, Anne-Laure Naneix, Ohad Ilovich, Jordan Cisneros, Krithika Rupanarayan, Frederick T Chin, Andrei Iagaru, Frederick M Dirbas, Amer Karam, Sanjiv S Gambhir","doi":"10.1177/1536012120939398","DOIUrl":"https://doi.org/10.1177/1536012120939398","url":null,"abstract":"An antigen binding fragment (BFab) derived from a tumor-associated mucin 1-sialoglycotope antigen (CA6) targeting antibody (huDS6) was engineered. We synthesized a companion diagnostic positron emission tomography (PET) tracer by radiolabeling BFab with [64Cu] to measure CA6 expression on cancer tissues prior to anti-human CA6 (huDS6-DM4 antibody-drug conjugate) therapy for ovarian and breast cancer patients. After chemotherapy, the ovarian patient received PET scan with 18F-2-fluoro-2-deoxyglucose ([18F]FDG: 10 mCi), followed by [64Cu]-DOTA-BFab ([64Cu]BFab; 5.5 mCi) 1 week later for PET scanning of CA6 expression and subsequent surgery. The breast cancer patient was treated with chemotherapy before primary tumor resection and subsequent [18F]FDG-PET scan. 4 weeks later the patient received of [64Cu]BFab (11.7 mCi) for CA6 PET scan. Whole body [18F]FDG-PET of the breast cancer patient indicated FDG-avid tumor metastases to the liver, bilateral hila and thoracic spine, but no uptake was observed for the ovarian patient. Each patient was also imaged by PET/CT with [64Cu]BFab at 1 and 24 hours after tracer administration. The [64Cu]BFab tracer was well tolerated by both patients without adverse effects, and no significant tracer uptake was observed in both patients. Immunohistochemistry (IHC) data indicated CA6 expressions were weak to intermediate and matched with the [64Cu]BFab-PET signals.","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"19 ","pages":"1536012120939398"},"PeriodicalIF":2.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012120939398","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38625616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

High-Efficiency Production of Radiopharmaceuticals via Droplet Radiochemistry: A Review of Recent Progress. 利用微滴放射化学高效生产放射性药物的研究进展

IF 2.8 4区医学

Molecular Imaging Pub Date : 2020-01-01 DOI: 10.1177/1536012120973099

Jia Wang, R Michael van Dam

引用次数: 11